Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Merck
Merck
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
Fierce Pharma
Mon, 05/1/23 - 10:16 am
AstraZeneca
Merck
Lynparza
metastatic castration-resistant prostate cancer
Merck beats first-quarter expectations on Keytruda, Gardasil strength
Reuters
Thu, 04/27/23 - 11:05 pm
Merck
earnings
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
BioSpace
Thu, 04/27/23 - 10:58 pm
Merck
AstraZeneca
FDA
Lynparza
metastatic castration-resistant prostate cancer
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Fierce Pharma
Wed, 04/26/23 - 05:50 pm
AbbVie
Amgen
Bristol Myers Squibb
Eli Lilly
Gilead Sceinces
JNJ
Merck
Pfizer
Regeneron
patents
activists
Merck, Glenmark wrap up Zetia pay-for-delay case after pharmacies take settlement
Fierce Pharma
Tue, 04/25/23 - 10:05 pm
Merck
Glenmark
Zetia
pay-for-delay
legal
In Zetia antitrust case, Merck and Glenmark ink deals with 2 plaintiff groups as retailers hold out
Fierce Pharma
Fri, 04/21/23 - 10:20 am
Merck
Glenmark
Zetia
pay-for-delay
antitrust
legal
Moderna and Merck’s mRNA Cancer Vaccine Impresses but Experts Urge Caution
BioSpace
Fri, 04/21/23 - 10:10 am
Moderna Therapeutics
Merck
MRNA
cancer vaccines
vaccines
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
Fri, 04/21/23 - 10:00 am
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A
Fierce Pharma
Tue, 04/18/23 - 10:10 pm
Big Pharma
M&A
Merck
Prometheus Biosciences
GSK
Bellus Health
In Pfizer's $43B acquisition of Seagen, the biotech's patience paid off
Fierce Pharma
Mon, 04/17/23 - 10:49 pm
Pfizer
Seagen
M&A
Merck
Merck’s latest deal turns up the spotlight on immune system drugmakers
BioPharma Dive
Mon, 04/17/23 - 10:47 pm
Merck
M&A
Prometheus Biosciences
immunology
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Biopharma Reporter
Mon, 04/17/23 - 12:05 pm
Merck
Moderna Therapeutics
cancer
cancer vaccines
Keytruda
clinical trials
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
BioPharma Dive
Sun, 04/16/23 - 11:31 pm
Merck
M&A
Prometheus Biosciences
IBD
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Wed, 04/12/23 - 11:39 am
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
Court Orders Merck to Produce Entire Database of Gardasil Adverse Events
EIN Newswires
Mon, 04/10/23 - 05:02 pm
legal
Merck
vaccines
Gardasil
Moderna Stock Yo-Yoes Winning A Key Battle For Its Cancer Vaccine
Investors Business Daily
Mon, 04/10/23 - 04:51 pm
Moderna Therapeutics
Merck
MRNA
cancer
vaccines
Europe
cancer vaccine
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Fri, 04/7/23 - 01:58 pm
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Proxygen, averaging a new collab every 10 months, sticks $2.5B molecular glue deal with Merck
Fierce Biotech
Wed, 04/5/23 - 10:09 am
Merck
Proxygen
molecular glue
protein degradation
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
BioSpace
Tue, 04/4/23 - 12:35 pm
Merck
Seagen
Astellas
Keytruda
Padcev
metastatic urothelial carcinoma
FDA
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »